Researchers have reported the first encouraging results of a gene therapy designed to treat cardiomyopathy associated with Friedreich's Ataxia, a rare genetic disease that progressively damages the heart and nervous system and is often fatal. The findings were published in JAMA Cardiology.

The study was conducted by a team at Weill Cornell Medicine. The therapy aims to replace a defective FXN gene, which is responsible for producing frataxin, a protein essential for cellular energy metabolism. A deficiency of frataxin primarily affects tissues with high energy demands, especially the heart and nervous system.

Friedreich’s ataxia is a rare autosomal recessive disorder in which a person inherits defective copies of the FXN gene from both parents. The disease typically begins in childhood and gradually leads to impaired coordination, speech, and mobility. However, the leading cause of death among affected individuals is often hypertrophic cardiomyopathy, a condition characterized by abnormal thickening of the heart muscle.

The phase I clinical trial enrolled 17 patients with cardiomyopathy related to Friedreich’s ataxia. Each participant received a single intravenous infusion of an adeno-associated viral (AAV) vector carrying a healthy copy of the FXN gene. This approach is designed to deliver the therapeutic gene primarily to heart tissue.

The results showed that the treatment was generally well tolerated. Several serious adverse events were reported, but all were resolved. Researchers noted that some of these events may have been related not to the gene therapy itself but to the immunosuppressive drug prednisone, which was administered to reduce immune reactions against the viral vector.

Biological markers provided early signs of potential effectiveness. Heart biopsies revealed increased frataxin levels, while imaging studies showed a reduction in left ventricular wall thickness, a key feature of cardiomyopathy. In addition, levels of cardiac troponin I, a marker of heart muscle injury, declined following treatment.

According to the investigators, some patients also demonstrated stabilization of neurological symptoms as measured by the mFARS scale. However, it remains unclear whether this effect resulted from direct action of the therapy on the nervous system or from indirect benefits of improved overall health.

Importantly, this was an early-stage clinical trial primarily designed to evaluate safety rather than definitive effectiveness. Nevertheless, the observed biological changes are being viewed as potentially meaningful signals of therapeutic benefit.

If future studies confirm these findings, the treatment could become one of the first disease-modifying therapies for Friedreich’s ataxia—addressing the underlying genetic defect rather than merely managing symptoms. Such an advance would represent a major milestone in the treatment of this devastating inherited disorder.